Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 478.78% and ...

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic.

Ozempic, Wegovy and Mounjaro featured prominently. Known for their use in managing type 2 diabetes and aiding weight loss for ...

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, manufactured by Novo Nordisk. Reuters Eli Lilly said Wednesday that its obesity drug Zepbound ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Comedian Nikki Glaser, host of the 2025 Golden Globe Awards ceremony, dove right in at the start of her opening monologue: ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.